Mutations of P53 Associated with Pancreatic Cancer and Therapeutic Implications

Overview

Journal Ann Hepatobiliary Pancreat Surg

Date 2021 Aug 17

PMID 34402431

Citations 18

Authors

Ioannis A Voutsadakis

Affiliations

Soon will be listed here.

Abstract

Pancreatic adenocarcinoma is a malignancy with rising incidence and grim prognosis. Despite improvements in therapeutics for treating metastatic pancreatic cancer, this disease is invariably fatal with survival time less than a few years. New molecular understanding of the pathogenesis of pancreatic adenocarcinoma based on efforts led by The Cancer Genome Atlas and other groups has elucidated the landscape of this disease and started to produce therapeutic results, leading to the first introduction of targeted therapies for subsets of pancreatic cancers bearing specific molecular lesions such as BRCA mutations. These efforts have highlighted that subsets of pancreatic cancers are particularly sensitive to chemotherapy. The most common molecular lesions in pancreatic adenocarcinomas are mutations in an oncogene and the gene that encodes for tumor suppressor protein p53. This paper will review the landscape of pancreatic cancers, focusing on mutations of p53, a major tumor suppressor protein, in pancreatic cancers and possible therapeutic repercussions.

Citing Articles

Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma.

Kluz N, Kraj L, Chmiel P, Przybylkowski A, Wyrwicz L, Stec R Cancers (Basel). 2024; 16(23).

PMID: 39682132 PMC: 11640600. DOI: 10.3390/cancers16233945.

A statistical approach for systematic identification of transition cells from scRNA-seq data.

Wang Y, Dede M, Mohanty V, Dou J, Li Z, Chen K Cell Rep Methods. 2024; 4(12):100913.

PMID: 39644902 PMC: 11704623. DOI: 10.1016/j.crmeth.2024.100913.

High p53 Protein Level Is a Negative Prognostic Marker for Pancreatic Adenocarcinoma.

Klein S, Bozko M, Toenniessen A, Rangno D, Bozko P Int J Mol Sci. 2024; 25(22).

PMID: 39596373 PMC: 11594790. DOI: 10.3390/ijms252212307.

An Atypical Case of Pancreatic Cancer with Mesenchymal Differentiation in a Patient with Primary Lung Adenocarcinoma: Insights into Tumor Biology and Novel Therapeutic Pathways.

Abbas N, Zahreddine L, Tawil A, Natout M, Shamseddine A Diagnostics (Basel). 2024; 14(22).

PMID: 39594178 PMC: 11592984. DOI: 10.3390/diagnostics14222512.

Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi-omics analysis.

Toyoda T, Miura N, Kato S, Masuda T, Ohashi R, Matsushita A Cancer Sci. 2024; 115(11):3622-3635.

PMID: 39259678 PMC: 11531968. DOI: 10.1111/cas.16302.

References

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

Ghosh B, Leach S . p53: Guardian of pancreatic epithelial identity. Cell Cycle. 2011; 10(11):1717. PMC: 3233485. DOI: 10.4161/cc.10.11.15686. View

Tang Y, Luo J, Zhang W, Gu W . Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell. 2006; 24(6):827-39. DOI: 10.1016/j.molcel.2006.11.021. View

Kinsey C, Camolotto S, Boespflug A, Guillen K, Foth M, Truong A . Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med. 2019; 25(4):620-627. PMC: 6452642. DOI: 10.1038/s41591-019-0367-9. View

Zhang B, Xu J, Li C, Shi S, Ji S, Xu W . MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer. Curr Mol Med. 2016; 16(4):404-11. DOI: 10.2174/1566524016666160316154150. View

Kobayashi M, Ishizaki Y, Owaki M, Matsumoto Y, Kakiyama Y, Hoshino S . Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line. Oncotarget. 2020; 11(18):1653-1665. PMC: 7210013. DOI: 10.18632/oncotarget.27581. View

Amelio I, Melino G . Context is everything: extrinsic signalling and gain-of-function p53 mutants. Cell Death Discov. 2020; 6:16. PMC: 7090043. DOI: 10.1038/s41420-020-0251-x. View

Voutsadakis I . The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer. J Biomed Sci. 2012; 19:67. PMC: 3418218. DOI: 10.1186/1423-0127-19-67. View

Bryant K, Stalnecker C, Zeitouni D, Klomp J, Peng S, Tikunov A . Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019; 25(4):628-640. PMC: 6484853. DOI: 10.1038/s41591-019-0368-8. View

10.

Matsushima S, Okita N, Oku M, Nagai W, Kobayashi M, Higami Y . An Mdm2 antagonist, Nutlin-3a, induces p53-dependent and proteasome-mediated poly(ADP-ribose) polymerase1 degradation in mouse fibroblasts. Biochem Biophys Res Commun. 2011; 407(3):557-61. DOI: 10.1016/j.bbrc.2011.03.061. View

11.

Conradt L, Henrich A, Wirth M, Reichert M, Lesina M, Algul H . Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death. Int J Cancer. 2012; 132(10):2248-57. DOI: 10.1002/ijc.27916. View

12.

Fukuda A . Molecular mechanism of intraductal papillary mucinous neoplasm and intraductal papillary mucinous neoplasm-derived pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2015; 22(7):519-23. DOI: 10.1002/jhbp.246. View

13.

Wang W, Friedland S, Guo B, ODell M, Alexander W, Whitney-Miller C . ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreas. Gut. 2018; 68(7):1245-1258. PMC: 6551318. DOI: 10.1136/gutjnl-2017-315541. View

14.

. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017; 7(8):818-831. PMC: 5611790. DOI: 10.1158/2159-8290.CD-17-0151. View

15.

Vena F, Jia R, Esfandiari A, Garcia-Gomez J, Rodriguez-Justo M, Ma J . MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. Oncotarget. 2018; 9(14):11592-11603. PMC: 5837749. DOI: 10.18632/oncotarget.24294. View

16.

Cassidy K, Bang S, Kurokawa M, Gerber S . Direct regulation of Chk1 protein stability by E3 ubiquitin ligase HUWE1. FEBS J. 2019; 287(10):1985-1999. PMC: 7226928. DOI: 10.1111/febs.15132. View

17.

Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S, Donadelli M . Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochim Biophys Acta. 2014; 1853(1):89-100. DOI: 10.1016/j.bbamcr.2014.10.003. View

18.

Diakopoulos K, Lesina M, Wormann S, Song L, Aichler M, Schild L . Impaired autophagy induces chronic atrophic pancreatitis in mice via sex- and nutrition-dependent processes. Gastroenterology. 2014; 148(3):626-638.e17. DOI: 10.1053/j.gastro.2014.12.003. View

19.

Kanayama M, Inoue M, Danzaki K, Hammer G, He Y, Shinohara M . Autophagy enhances NFκB activity in specific tissue macrophages by sequestering A20 to boost antifungal immunity. Nat Commun. 2015; 6:5779. PMC: 4304414. DOI: 10.1038/ncomms6779. View

20.

Blackford A, Parmigiani G, Kensler T, Wolfgang C, Jones S, Zhang X . Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res. 2009; 69(8):3681-8. PMC: 2669837. DOI: 10.1158/0008-5472.CAN-09-0015. View